tetano
Editor, Senior Moderator
Sci Rep
. 2025 Feb 10;15(1):4995.
doi: 10.1038/s41598-025-89012-1. A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay
Xiaoqin Yao[SUP] 1 2 3 4 [/SUP], Hao Xu[SUP] 1 2 3 [/SUP], Qin Du[SUP] 1 2 3 [/SUP], Xiaolan Lu[SUP] 1 2 3 [/SUP], Qiang Wang[SUP] 5 6 7 [/SUP]
Affiliations
A novel method was proposed based on gold immune chromatography assay (GICA) including the detection of antibodies targeting different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epitopes to improve the SARS-CoV-2 IgM and IgG detection performance. Sera from 282 confirmed Coronavirus Disease 2019 (COVID-19) patients were obtained at different times as the SARS-CoV-2 IgM or IgG experimental group. Sera from 148 uninfected and unvaccinated individuals were used as the control. The serum single-epitope IgM and IgG antibodies against SARS-CoV-2 were detected via GICA; the two epitope antibodies with high detection performance were used to construct a novel method, and then compared with the chemiluminescence immunoassay (CLIA). The diagnostic specificity and screening sensitivity of S2-IgM and N-IgM combined detection of serum SARS-CoV-2 IgM antibodies based on GICA were 99.32% and 98.81%, respectively, which were higher than those of the CLIA test (83.78% and 82.14%; P < 0.001). The diagnostic specificity of RBD-IgG and N-IgG combined detection in the serum was 100.00%, the same as that of CLIA. The novel method showed excellent screening sensitivity and diagnostic specificity for serum SARS-CoV-2 IgM and IgG, effectively avoiding omissions and misdiagnoses in the early clinical stages of screening and diagnosing COVID-19.
Keywords: Chemiluminescence Immunoassay; Diagnostic specificity; Gold Immune Chromatography Assay; SARS-CoV-2 IgG antibody; SARS-CoV-2 IgM antibody; Screening sensitivity.
. 2025 Feb 10;15(1):4995.
doi: 10.1038/s41598-025-89012-1. A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay
Xiaoqin Yao[SUP] 1 2 3 4 [/SUP], Hao Xu[SUP] 1 2 3 [/SUP], Qin Du[SUP] 1 2 3 [/SUP], Xiaolan Lu[SUP] 1 2 3 [/SUP], Qiang Wang[SUP] 5 6 7 [/SUP]
Affiliations
- PMID: 39929938
- DOI: 10.1038/s41598-025-89012-1
A novel method was proposed based on gold immune chromatography assay (GICA) including the detection of antibodies targeting different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epitopes to improve the SARS-CoV-2 IgM and IgG detection performance. Sera from 282 confirmed Coronavirus Disease 2019 (COVID-19) patients were obtained at different times as the SARS-CoV-2 IgM or IgG experimental group. Sera from 148 uninfected and unvaccinated individuals were used as the control. The serum single-epitope IgM and IgG antibodies against SARS-CoV-2 were detected via GICA; the two epitope antibodies with high detection performance were used to construct a novel method, and then compared with the chemiluminescence immunoassay (CLIA). The diagnostic specificity and screening sensitivity of S2-IgM and N-IgM combined detection of serum SARS-CoV-2 IgM antibodies based on GICA were 99.32% and 98.81%, respectively, which were higher than those of the CLIA test (83.78% and 82.14%; P < 0.001). The diagnostic specificity of RBD-IgG and N-IgG combined detection in the serum was 100.00%, the same as that of CLIA. The novel method showed excellent screening sensitivity and diagnostic specificity for serum SARS-CoV-2 IgM and IgG, effectively avoiding omissions and misdiagnoses in the early clinical stages of screening and diagnosing COVID-19.
Keywords: Chemiluminescence Immunoassay; Diagnostic specificity; Gold Immune Chromatography Assay; SARS-CoV-2 IgG antibody; SARS-CoV-2 IgM antibody; Screening sensitivity.